Basal ganglia calcification in a patient with static encephalopathy of childhood with neurodegeneration in adulthood/β‐propeller protein‐associated neurodegeneration

2020 ◽  
Vol 8 (5) ◽  
pp. 332-334
Author(s):  
Fujio Umehara ◽  
Kazuhiro Iwama ◽  
Takeshi Mizuguchi ◽  
Naomichi Matsumoto

2014 ◽  
Vol 36 (9) ◽  
pp. 823-825 ◽  
Author(s):  
Makoto Ishitobi ◽  
Masao Kawatani ◽  
Mizuki Asano ◽  
Hirotaka Kosaka ◽  
Takashi Goto ◽  
...  


2014 ◽  
Vol 35 (8) ◽  
pp. 964-971 ◽  
Author(s):  
Monica Sanchez-Contreras ◽  
Matthew C. Baker ◽  
NiCole A. Finch ◽  
Alexandra Nicholson ◽  
Aleksandra Wojtas ◽  
...  


Neurology ◽  
2006 ◽  
Vol 66 (4) ◽  
pp. 615-616 ◽  
Author(s):  
M. M. Bianchin ◽  
J. E. Lima ◽  
J. Natel ◽  
A. C. Sakamoto ◽  
H. Klunemann ◽  
...  


2019 ◽  
Vol 7 (12) ◽  
pp. 1483-1491
Author(s):  
Seiju Kobayashi ◽  
Kumiko Utsumi ◽  
Masaru Tateno ◽  
Tomo Iwamoto ◽  
Tomonori Murayama ◽  
...  


Author(s):  
Benjamin Kwan ◽  
Bernard Champion ◽  
Steven Boyages ◽  
Craig F Munns ◽  
Roderick Clifton-Bligh ◽  
...  

Summary Autosomal dominant hypocalcaemia type 1 (ADH1) is a rare familial disorder characterised by low serum calcium and low or inappropriately normal serum PTH. It is caused by activating CASR mutations, which produces a left-shift in the set point for extracellular calcium. We describe an Australian family with a novel heterozygous missense mutation in CASR causing ADH1. Mild neuromuscular symptoms (paraesthesia, carpopedal spasm) were present in most affected individuals and required treatment with calcium and calcitriol. Basal ganglia calcification was present in three out of four affected family members. This case highlights the importance of correctly identifying genetic causes of hypocalcaemia to allow for proper management and screening of family members. Learning points: ADH1 is a rare cause of hypoparathyroidism due to activating CASR mutations and is the mirror image of familial hypocalciuric hypercalcaemia. In patients with ADH1, symptoms of hypocalcaemia may be mild or absent. Basal ganglia calcification may be present in over a third of patients. CASR mutation analysis is required for diagnostic confirmation and to facilitate proper management, screening and genetic counselling of affected family members. Treatment with calcium and activated vitamin D analogues should be reserved for symptomatic individuals due to the risk of exacerbating hypercalciuria and its associated complications.



1985 ◽  
Vol 48 (1) ◽  
pp. 61-64 ◽  
Author(s):  
S Takashima ◽  
L E Becker


2016 ◽  
Vol 29 (3) ◽  
pp. 139-143 ◽  
Author(s):  
Amir A. Mufaddel ◽  
Ossama T. Osman ◽  
Ghanem Al-Hassani ◽  
Shakhbout Al-Bedwawi ◽  
M. Jawad Hashim


2018 ◽  
Vol 388 ◽  
pp. 150-154 ◽  
Author(s):  
Isao Hozumi ◽  
Hisaka Kurita ◽  
Kazuhiro Ozawa ◽  
Nobuyuki Furuta ◽  
Masatoshi Inden ◽  
...  




Sign in / Sign up

Export Citation Format

Share Document